Article
Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression.
Endocrinology - 1 Jan 1999
Trouillas J, Chevallier P, Remy C, Rajas F, Cohen R, Calle A, Hooghe-Peters E L, Rousset B
Abstract excerpt
Dopamine (Da) and Da agonists are known to inhibit secretion and proliferation of normal and tumoral PRL cells, through receptors of D2 subtype. Because of the lack of an experimental model, the relationship between bromocriptine (BR) sensitivity and D2 receptor expression is poorly documented. S...
Topics
- Animals
- Bromocriptine
- Cell Differentiation
- Cell Division
- Dopamine Agonists
- Female
- Growth Hormone
- Humans
- Immunohistochemistry
- In Situ Hybridization
- Neoplasm Transplantation
- Phenotype
- Pituitary Neoplasms
- Prolactin
- Rats